Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Patent Settlements: FTC Gets Teva To Eschew 'No-Authorized Generic' Deals

Executive Summary

Global settlement resolves charges against Teva in three pending FTC antitrust suits and expands terms of 2015 consent decree.

You may also be interested in...



Teva Slapped With €60m Fine Over Unlawful EU Provigil Delay

Teva received a “package of commercial side-deals” for agreeing to halt generic competition to Cephalon’s Provigil (modafinil) throughout the EU, which it “would not have achieved without committing to staying out of the market,” according to findings by the European Commission.

FTC Claims Revived Over Teva-AbbVie 'Pay For Delay' Deal

AbbVie and FTC both see wins and setbacks in Third Circuit ruling on case involving reverse-payment patent settlement with Teva.

AndroGel $448M Pay-For-Delay Disgorgement Spiked On Appeal, But Some Of FTC Complaint Resurrected

AbbVie and FTC both see wins and setbacks in Third Circuit ruling on case involving reverse-payment patent settlement with Teva.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS124792

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel